Cancer Supportive Care Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Cancer Supportive Care Drugs Market is segmented by Drug Class (G-CSFs, ESAs, Antiemetics, Bisphosphonates, Opioids, NSAIDs, and Other Drug Classes) and by Geography.

Market Snapshot

Cancer Supportive Care Drugs Market Snapshot
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 3.56 %
Cancer Supportive Care Drugs Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

According to the World Health Organization (WHO), there are an estimated 18.1 million new cases of cancer registered in 2018, and about 9.6 million deaths were also recorded in 2018 which were regarded to cancer. Moreover, statistics also report an increasing prevalence of cancer over the years. This has lead to an increase in the number of patients going for cancer therapies. But, cancer therapies have been associated with many side effects. Cancer supportive care drugs are used to alleviate the side effects of cancer therapy. Hence increasing prevalence of cancer can be directly associated with the growth of this market. Rising disposable income and improved healthcare structure have also helped people to access the cancer supportive care drugs, which is also helping this market grow.

However, technological advancements in targeted therapy drugs, which have lesser side effects than traditional cancer therapy drugs, are being adopted at a faster rate. This has directly affected the growth of the cancer supportive drugs market. Other factors like side effects from cancer supportive drugs and stringent regulatory processes have also contributed as restraining factors to this market.

Scope of the Report

Cancer supportive care drugs are used to mitigate the harmful side effects of cancer treatment by protecting certain cells or organs. In the report, a detailed analysis of the cancer supportive care drugs market is provided. The market is segmented by drug class, and geography.

By Drug Class
G-CSFs (Granulocyte colony-stimulating factor)
ESAs (Erythropoiesis stimulating agent)
NSAIDs (Non Steroidal Anti-Inflammatory Drugs)
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

G-CSF is expected to register High Growth over the Forecast Period

G-CSF is a type of growth factor that helps the bone marrow to produce white blood cells to reduce the risk of infection after some types of cancer treatment. G-CSF also makes stem cells move from the bone marrow into the blood. Stem cells are the cells in the bone marrow that are responsible for the production of red blood cells, white cells and platelets.

G-CSF is administered to stimulate the bone marrow to produce stem cells and release them into the blood. The stem cells are then collected before proceeding to have high dose chemotherapy. The high dose of chemotherapy stops your bone marrow producing blood cells. Hence, the collected stem cells are used in stem cell transplant to restore the functioning of bone marrow.

As G-CSF helps to restore the functioning of the bone marrow which is essential for the production of red blood cells, white cells and platelets, the drug class is being adopted widely. Owing to these factors and increasing prevalence of cancer (as per the Center for Disease Control and Prevention, 2018), this market is expected to grow in the forecast period.

Cancer Supportive Care Drugs Market Trends

North America dominates the market

North America has one of the highest prevalence of cancer in the world. According to the National Institute of Health, the prevalence of cancer in 2018 was estimated to be 439.2 per 100,000 in the United States. According to the Canadian Cancer Society, an estimated that 206,200 new cancer diagnosed and 80,800 deaths from cancer occurred in Canada in 2017.

Although high prevalence leads to a burden on the population of the country, US and Canada have developed healthcare systems and hence spend a lot for the treatment and research in the oncology field. Hence, these countries attract a lot of market players.

Cancer Supportive Care Drugs Market Growth

Competitive Landscape

Majority of the cancer supportive care drugs are being manufactured by the global key players. Market leaders with more funds for research and better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing an emergence of some small players, which has helped the market growth in these regions and has also increased competition for market share.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Large Number of Side-effects Associated with Cancer Treatment

      2. 4.2.2 Rising Disposable Incomes and Constant Improvements in Healthcare Infrastructure

      3. 4.2.3 Increasing Prevalence of Cancer

    3. 4.3 Market Restraints

      1. 4.3.1 Advancements in Targated Therapy Drugs

      2. 4.3.2 Side Effects of Supportive Care Drugs

      3. 4.3.3 Stringent Regulatory Process

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Drug Class

      1. 5.1.1 G-CSFs (Granulocyte colony-stimulating factor)

      2. 5.1.2 ESAs (Erythropoiesis stimulating agent)

      3. 5.1.3 Antiemetics

      4. 5.1.4 Bisphosphonates

      5. 5.1.5 Opioids

      6. 5.1.6 NSAIDs (Non Steroidal Anti-Inflammatory Drugs)

      7. 5.1.7 Topical

      8. 5.1.8 Others

    2. 5.2 Geography

      1. 5.2.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.2.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.2.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.2.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Amgen Inc.

      2. 6.1.2 Helsinn Healthcare

      3. 6.1.3 Heron Pharma

      4. 6.1.4 Johnson & Johnson

      5. 6.1.5 Merck & Co. Inc

      6. 6.1.6 Novartis (Sandoz)

      7. 6.1.7 F. Hoffmann-La Roche AG

      8. 6.1.8 Tesaro

      9. 6.1.9 Sanofi

      10. 6.1.10 Sun Pharmaceutical Industries Ltd.

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Cancer Supportive Care Drugs Market market is studied from 2018 - 2026.

The Cancer Supportive Care Drugs Market is growing at a CAGR of 3.56% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Amgen Inc., Novartis AG, Merck & Co. Inc, F. Hoffmann-La Roche AG, Johnson & Johnson are the major companies operating in Cancer Supportive Care Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!